Literature DB >> 12684313

Evaluation of outcome in critically ill patients with nosocomial enterobacter bacteremia: results of a matched cohort study.

Stijn I Blot1, Koenraad H Vandewoude, Francis A Colardyn.   

Abstract

STUDY
OBJECTIVE: To evaluate the clinical impact of nosocomial Enterobacter bacteremia in critically ill patients.
DESIGN: Retrospective (January 1992 to December 2000) matched cohort study.
SETTING: Fifty-four-bed ICU (including medical, surgical, cardiosurgical ICU, and burns unit) from a university hospital. PATIENTS: Sixty-seven ICU patients with Enterobacter bacteremia (case patients) and 134 control patients. INTERVENTION: Matching of control patients (1:2 ratio) was on the basis of the APACHE (acute physiology and chronic health evaluation) II system. As expected, mortality can be derived from this severity-of-disease classification system; this matching procedure results in an equal expected mortality rate for patients with Enterobacter bacteremia and control patients.
RESULTS: The overall rate of appropriate antibiotic therapy in patients with Enterobacter bacteremia was high (96%) and initiated soon after the onset of the bacteremia (0.5 +/- 0.9 days). Patients with Enterobacter bacteremia had more hemodynamic instability (p = 0.015), longer ICU stay (p < 0.001), and ventilator dependence (p < 0.001). No differences between case and control patients were found in age (52 years vs 53 years, p = 0.831), prevalence of acute renal failure (16% vs 16%, p = 0.892), and acute respiratory failure (93% vs 84%, respectively; p = 0.079). In-hospital mortality rates for case and control patients were not different (34% vs 39%, respectively; p = 0.536).
CONCLUSION: After accurate adjustment for severity of underlying disease and acute illness, no difference was found between ICU patients with Enterobacter bacteremia and matched control patients. In the presence of fast and appropriate antibiotic therapy, Enterobacter bacteremia does not adversely affect the outcome in ICU patients.

Entities:  

Mesh:

Year:  2003        PMID: 12684313     DOI: 10.1378/chest.123.4.1208

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality.

Authors:  John R Prowle; Jorge E Echeverri; E Valentina Ligabo; Norelle Sherry; Gopal C Taori; Timothy M Crozier; Graeme K Hart; Tony M Korman; Barrie C Mayall; Paul D R Johnson; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-03-21       Impact factor: 9.097

2.  Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients.

Authors:  Koenraad H Vandewoude; Stijn I Blot; Pieter Depuydt; Dominique Benoit; Werner Temmerman; Francis Colardyn; Dirk Vogelaers
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

3.  Community-acquired versus nosocomial Klebsiella pneumonia bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance.

Authors:  Dominique M Vandijck; Johan M Decruyenaere; Pieter O Depuydt; Stijn I Blot
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153

4.  Intensive care unit-acquired bacteremia in mechanically ventilated patients: clinical features and outcomes.

Authors:  Hsin-Kuo Ko; Wen-Kuang Yu; Te-Cheng Lien; Jia-Horng Wang; Arthur S Slutsky; Haibo Zhang; Yu Ru Kou
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

5.  Identification of bacterial contaminants in polyherbal medicines used for the treatment of tuberculosis in Amatole District of the Eastern Cape Province, South Africa, using rapid 16S rRNA technique.

Authors:  Elizabeth Bosede Famewo; Anna Maria Clarke; Anthony Jide Afolayan
Journal:  J Health Popul Nutr       Date:  2016-08-22       Impact factor: 2.000

6.  Attributable mortality of ICU acquired bloodstream infections: a propensity-score matched analysis.

Authors:  Nicolas Massart; Guilhem Wattecamps; Mikael Moriconi; Pierre Fillatre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-10       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.